PT - JOURNAL ARTICLE AU - Sun, Liting AU - Xian, Hang AU - Shi, Yunxin AU - Yang, Taotan AU - Shuai, Hongyan AU - Xia, Ruilong AU - Wen, Ting AU - Xia, Wei AU - Qian, Ran AU - Zhu, Fengting AU - Liu, Yuanying AU - Tian, Zhicheng AU - Li, Lamei AU - Cong, Rui AU - Luo, Ceng AU - Wu, Shengxi AU - Shen, Xiafeng AU - Yu, Xin AU - Xie, Rou-Gang AU - Peng, Changgeng TI - Nav1.7 and Nav1.8 form supramolecular active clusters with TRKB in mouse and human DRG neurons during development of neuropathic pain AID - 10.1101/2022.11.05.22281929 DP - 2022 Jan 01 TA - medRxiv PG - 2022.11.05.22281929 4099 - http://medrxiv.org/content/early/2022/11/11/2022.11.05.22281929.short 4100 - http://medrxiv.org/content/early/2022/11/11/2022.11.05.22281929.full AB - Neuropathic pain affects 7-10% of the global population, and one of its characteristics is sensitization of somatosensory nervous system. Altered expression of ion channels and receptors has been found to be involved in neuronal hyperexcitability after injury to somatosensory nervous system, it is, however, unknown that if ion channels and receptors could gain qualitative changes on the level of structure organization when they are excessively expressed in same one neuron during the development of neuropathic pain. Here we show first that not only the expression of voltage-gated sodium channels Nav1.7 (SCN9A), Nav1.8 (SCN10A) and TRKB (also named NTRK2) increased in DRG neurons of patients with over 3-month severe neuropathic pain induced by brachial plexus avulsion (BPA), but also Nav1.7 and Nav1.8 formed supramolecular active clusters with or without TRKB in DRG neurons of mice with chronic neuropathic pain induced by spared nerve injury or diabetic neuropathy and of BPA pain patients with neuropathic pain. Nav1.7, Nav1.8 and TRKB might function in a coordinated manner in orderly organized supramolecular active clusters to geometrically increase the hyperexcitability of pathological DRG neurons. Our findings suggest that supramolecular active clusters of Nav1.7, Nav1.8 and TRKB might need be targeted for curing neuropathic pain, and that inhibition of both Nav1.7 and Nav1.8 might be required to achieve efficient relief of neuropathic pain.Competing Interest StatementThe authors have declared no competing interest.Funding StatementChanggeng Peng is supported by the National Natural Science Foundation of China (32070977, 51971236, 31871063), and National Major Science and Technology Projects of China (2018ZX09733001-006-005). Liting Sun is supported by the National Natural Science Foundation of China (82101320). Rougang Xie is supported by the National Natural Science Foundation of China (82171212, 81870867) and Ministry of Science and Technology of China (2021ZD0203205). Hongyan Shuai is supported by the National Natural Science Foundation of China (82060149).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The avulsed roots of the affected brachial plexus and the dislocated cervical DRG tissues were resected during the surgical process of nerve reconstruction or transplantation under the ethic permit (KY20222228) approved by the Ethics Committee of Xijing Hospital, the first affiliated hospital of Fourth Military Medical University. Normal cervical DRG tissues from naturally aborted 29-weeks human embryos were collected according to the ethic permit (MECDU-201909-1) approved by Dali University.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.